MMM 2Q18 earnings

Key Takeaways:

MMM reported 2Q18 revenue that were better than expected, with EPS in line after removing the one-time gain from the sale of its Communications Markets business. Revenue grew +7.4% y/y (+5.6% organic ex-FX), gross margins expanded by 120bps y/y, and operating margin increased 100bps mostly from better volume and productivity actions. Sales growth was broad based, with all segments seeing organic growth. Some of the beat this quarter was due to US customers accelerating their purchases ahead of an ERP roll-out in the US in Industrials, Safety & Graphics and Electronics & Energy (this has been implemented in Europe in the last 18 months). The impact from this implementation is a +50-100bps of growth pulled forward to 2Q18. Adjusted EPS grew 27% y/y thanks to organic growth, productivity efforts and a lower tax rate.

MMM returned $2.4B to shareholders via dividends and share repurchases this quarter. The management team increased the lower end of its share repurchase guidance to $4-5B from $3-5B.

The stock initially sold off as the management team adjusted its top-end EPS guidance for the year due to the sale of a business, but recovered since as the underlying fundamentals remain strong. Overall MMM has some good momentum in its pricing power, offsetting raw-material inflation. The new tariffs have little effect so far on the company’s costs, only estimated at 1c/share. However the management team is monitoring the impact from any increase in tariffs and possible retaliations, and could change sourcing and/or pricing increases if necessary. We are not changing our price target or position size at this point.

Continue reading “MMM 2Q18 earnings”

SLB 2Q18 earnings satisfactory, FCF improvement towards the end of the year

Key Takeaways:

Schlumberger 2Q18 earnings results were generally in line with expectations, with revenue +6% quarter/quarter, and margin +75bps q/q. Technology and software, differentiating factors for SLB’s margins, were offset by startup costs and transitory operational delays. Cameron (offshore activity) is slow to rebound, but should contribute to growth in 2018-2019. Management had a positive outlook for its international business, seeing positive pricing trends, projecting it to strengthen in 4Q. Initial guidance is for double digit growth in its international business in 2019, while capex needs remain at $2B, lifting the company’s FCF. Its equipment will be fully deployed by the 4th quarter, setting the stage for greater pricing power in 2019. However, its North American geography is projected to get worse before it gets better. During the quarter, SLB repurchased 1.5M shares. On the negative side, 3Q18 guidance came below consensus, with EPS up 10-15% q/q. Overall we are pleased with the results, and believe patience is key with this stock to see improving free cash flow.

SLB Thesis:

1. After 5 years of significant underperformance, The Energy Sector is historically cheap and SLB is

historically cheap relative to the sector – despite being one of the highest quality Energy companies

in the world

2. As the leading Global Oil Services company, SLB is well positioned to benefit from (1) Secular

growth in U.S. shale production and (2) Cyclical rebound in global oil production/oil prices

3. SLB is a high quality company within a highly cyclical industry – SLB has generated 16% annual

Returns on Invested Capital over the past 10 years and throws off a lot of free cash flow

4. SLB’s stock is highly levered to increasing oil prices and will not wait for the turn to make its

move. We are also getting closer to a bottom in EPS estimates and SLB protects better than most

energy stocks on the downside due to its high quality nature – strong balance sheet, ROIC, cash

flows

$SLB.US

[tag SLB]

Julie S. Praline

Director, Equity Analyst

Direct: 617.226.0025

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

PLEASE NOTE!

We moved! Please note our new location above!

UNP 2Q18 earnings recap: underlying business trend is good, one-time items hit its operating ratio

Key Takeaways:

UNP reported revenue growth of 8%, but an operating ratio of 63% above consensus of 62% (lower is better). Fuel prices had a negative impact on margin of -100 bps (fuel costs +48% y/y), as the company passes on the increased fuel expenses to clients with a lag. The services related costs increase offset the productivity gains this quarter. UNP noted some one-time challenges that impacted performance: a tunnel collapse being out of service from May 29 to June 20 (this added 4-5 days for some freight as trains had to be re-routed), and train-crew shortages (which is improving). While those costs should persist in 3Q, overall 2H should show some productivity gains. Another negative point highlighted during the call was the decline in Permian volumes Frac Sand, as local sand mines come online. Freight revenue experienced positive performance: +4% volume (accelerating from 2% in 1Q18), +2% core pricing, +3.5% fuel surcharge, and a -1% mix impact. Free cash flow was better than expected, but helped by lower capex than estimates. The management team is more positive in its business environment outlook, and lifted its volume growth guidance for 2018 to low-to-mid single digit growth (from low single digit).

Volume growth will be supported by:

o future plastic shipments (chemical plants coming on stream)

o truck drivers shortages pushing conversion to rail in intermodal

o e-commerce supporting shipment of parcels.

So far UNP is being lifted by positive trends lifting volumes and prices, but a couple of one-time items impacted its productivity, masking any improvement in its operating ratio. We will monitor the fuel cost increase to make sure it is being passed on to customers in the coming quarters. We are not lifting our price target at this time, as we need to see its operating ratio improve at this stage of the economic cycle.

Continue reading “UNP 2Q18 earnings recap: underlying business trend is good, one-time items hit its operating ratio”

CVS – 2 causes for today’s weakness

CVS is seeing some pressure today as the FTC chairman said Aetna and CVS shouldn’t get a free pass because this is a vertical integration. Just a reminder that UnitedHealth is already a vertical integration at play, and has never been highlighted as being anti-competitive.

There are also comments coming from a proposed regulation entitled “removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection” (wow that was long to type!). Details are not currently available. This is yet another push from the Trump administration to reform the healthcare system. Drugmakers are seeing pressure too and trying to avoid damages to their business models: Pfizer and Novartis recently announced holding off raising prices for the rest of 2018, in response to Trump’s attacks.

As a reminder, a key function of the PBM is to leverage scale and competition to reduce drug costs for clients. PBM keep up to 10% of the “saving”, although CVS mentioned being closer to 5%. Per Goldman Sachs, the rebates business represents a mid-single digit % of its EBITDA. Below is Goldman’s calculation:

[tag CVS}

$CVS.US

Julie S. Praline

Director, Equity Analyst

Direct: 617.226.0025

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

PLEASE NOTE!

We moved! Please note our new location above!

JNJ 2Q18 earnings results strong thanks to growth in Pharma

Key Takeaways:

JNJ reported 2Q18 earnings results that beat consensus thanks to very strong Pharma sales (+17.6% organic). Medical Devices grew 1.9% organic, still experiencing weakness in diabetes and Ortho. Their consumer segment is still showing weak growth, but the re-launch of the baby care business in the US should help lift sales in the coming quarters. JNJ has now experienced its 5th consecutive quarter of sales growth acceleration, as new drugs gains are over time offsetting older drugs facing generics competition (although 2H18 should see increased generics pressure). Guidance for operational sales growth in 2018 is up slightly, now 4.5-5.5% from 4-5%, and EPS guidance was lifted by 2 cents. Reported numbers will see more impact from currency however. As Pespi’s CEO did last week, JNJ’s CEO mentioned their recently released ESG report “Health for Humanity” during his presentation.

Continue reading “JNJ 2Q18 earnings results strong thanks to growth in Pharma”

Pepsi 2Q18 earnings: some relief from good growth but margins going forward still need monitoring

Key Takeaways:

Pepsi released Q2 earnings that were better than expected (granted on recently lowered sell-side expectations). Organic growth was +2.6% (consensus +2.2%). North America beverages remains soft, but saw sequential improvements following additional advertising efforts + new products (Bubly and Gatorade Zero), and should see continued positive momentum in 2H18. Frito Lay’s good performance in price and volume helped lift the overall company’s gross margin (positive mix impact). The emerging markets had strong growth +6% even with the Brazil truck driver strike limiting distribution of goods. As I had mentioned leading up to this earnings season, the company (as well as other consumer staples) is experiencing higher commodity and freight costs. Since a good portion of this quarter’s growth came from one-time items (Thailand beverage refranchising for example), the quality of growth going forward needs to be monitored. The company reiterated its FY18:

ü organic revenue growth of at least +2.3%

ü EPS +9% y/y.

Continue reading “Pepsi 2Q18 earnings: some relief from good growth but margins going forward still need monitoring”

McCormick 2Q18 recap

Key Takeaways:

Last week McCormick released its 2Q18 earnings, with a sales and gross margin beat (+340bps y/y à leading to a 330bps operating margin expansion) and EPS +24% y/y. Revenue ex-FX grew 16% (+13% from the addition of Frank’s and French’s brands), driven by +2.5% volume/mix and 0.5% price. China had the strongest Consumer segment growth with +5.7% volume growth. In its Flavor segment, Americas was the leading geography with +5.3% volume growth. The addition of new brands helped expand the company’s overall margins. MKC reduced its cash conversion cycle by 9 days, a sign of good cash flow management skills, supporting faster debt pay down.

Continue reading “McCormick 2Q18 recap”

Fortive to acquire JNJ’s ASP medical sterilization unit

We had been waiting for Fortive’s next deal following the divestiture of its Automation & Specialty business to Altra for $3B. It was announced last night with the acquisition of JNJ’s medical sterilization unit for $2.7B. The deal is expected to close by early 2019. The EBITDA from the new business will offset the loss from the divested Automation business. The deal will be financed by cash on hand, new debt and/or equity.

What is the JNJ’s Advanced Sterilization Products business?

· Provides innovative sterilization and disinfection solutions and low temp hydrogen peroxide sterilization technology:

o Terminal sterilization: Manufactures capital equipment as well as accompanying proprietary sterilant cassettes, biological indicators and software that sterilize critical devices including laparoscopic and robotic instruments and stainless steel instruments. Installed base of >21k units with 8-10 year life.

o High-level disinfection: Manufactures cleaners, reprocessors and biocides for semi-critical devices such as endoscopes. Installed base of >9k units with 6-8 year life cycle.

o Services: Provides maintenance and repair of sterilization solutions ensuring critical uptime for hospitals.

· Global market leader with 80% recurring revenue base (in line with FTV growth strategy), a large installed customer base and good brands

· Provides entry into the medical sterilization and disinfection market:

o Strong growth sector

o International growth

· Expected to achieve 10% ROIC in 4 years

This unit hasn’t grown in the several years, in a market that grows mid-single digit. Being part of a large corporation such as JNJ, the unit might not have been a critical business the company was focused on. With $775M in sales last year, it is in line with FTV’s business unit size in the $1B range. EBITDA margin is 25%, which should be accretive to FTV right away.

We see this deal as positive for FTV, expanding its exposure in the non-cyclical medtech sector.

$FTV.US

[tag FTV]

Julie S. Praline

Director, Equity Analyst

Direct: 617.226.0025

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

PLEASE NOTE!

We moved! Please note our new location above!

UNP Analyst Day Takeaways

Below is the summary of the positive data points that came out of yesterday’s analyst day:

· Management initiated a 60% Operating Ratio in 2020 (they walked away from their prior 60% by 2019 last quarter)

· Cadence of share repurchase is more aggressive than previously announced: $20B through 2020, and funded mostly from free cash flow

· Lower capex results in higher free cash flow conversion

· Dividend increase (implied to go to 2.5% from 2%)

· Leverage is going up from 2x to 2.7x. Management was reassuring that this increase would be gradual, and that they would remain prudent if the macro environment turns negative.

All these positive news might seem aggressive knowing that UNP didn’t meet its latest volume and operating ratio guidance, but we would assume they learned from that mistake and provided an update on guidance they feel comfortable achieving.

Below is GS valuation analysis, which shows UNP as being cheaper than peers assuming UNP meets its guidance on volume, pricing, OR and buybacks:

Julie S. Praline

Director, Equity Analyst

Direct: 617.226.0025

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

PLEASE NOTE!

We moved! Please note our new location above!

Medtronic MDT reported strong 4Q FY18 results and a conservative initial FY19 guidance

Thesis intact. Key takeaways from the quarter:

Medtronic reported strong 4Q FY18 sales and earnings results this morning with +6.5% organic sales growth and +6.5% EPS growth. Top line growth was robust across all segments, with Diabetes impressive at +21% (thanks to US patient demand for its insulin pump). Operating margin expanded (+80bps) in the quarter, thanks to cost savings initiatives.

The initial FY19 organic sales growth guidance of +4-4.5% is achievable and leaves room for upside, while operating margin should expand by 50bps (better than FY18 +20bps) and EPS growth in the +8-9% range. Management thinks that its emerging market business will grow in the low double digits going forward, following a +15.5% growth in 4Q. Free cash flow conversion will improve going forward, as litigation and tax payments diminish. The tax reform will push for more overseas assets liquidation to continue.

In an interesting move, MDT hired Michael Weinstein earlier this month, a well-regarded sell-side analyst (JP Morgan), to lead its strategy. He’s bringing a deep knowledge of the medtech space, and we can expect some M&A/divestiture/capital allocation moves in the coming year. The next catalyst will be when the company introduces its long-term outlook during its investor day on June 5th.

Valuation unchanged, we are maintaining our $93 price target, reflecting the recent strength in the business.

Continue reading “Medtronic MDT reported strong 4Q FY18 results and a conservative initial FY19 guidance”